News | Heart Valve Technology | January 11, 2018

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System

System recalled for mold overflow defect that may embolize and obstruct blood flow

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System

January 11, 2018 — The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery System due to a molding overflow defect in the button valve within the loader. The overflow material could detach during placement of the delivery system and potentially embolize into the patient, according to the FDA. Such an embolism could obstruct blood flow to critical organs, leading to serious injury and/or a need to surgically extract the overflow material from the patient. In dire situations, severe neurologic, cardiac, limb, renal or gastrointestinal injury may result.

The recall encompasses select lot numbers between 60677270 and 60990824, with manufacturing dates between Nov. 22, 2016 to July 10, 2017, and distribution dates between Jan. 9, 2017 to July 17, 2017.

On July 21, 2017, Edwards LifeSciences sent affected customers a "Recall Notification Letter" informing them of the device's risks. In the letter, Edwards LifeSciences directed customers to:

  • Complete the "Acknowledgement Form" that accompanied the Recall Notification Letter.
  • Check all inventory for affected models of the Certitude Delivery System.
  • Return the "Acknowledgement Form" and all affected models of the Certitude Delivery System to Edwards LifeSciences as indicated in the Recall Notification Letter.

The Edwards LifeSciences Certitude Delivery System is used for delivery of the Edwards Sapien 3 transcatheter heart valve (THV), typically used during a transcatheter aortic valve replacement (TAVR).

The system includes a balloon catheter that expands a compressed (crimped) THV, a loader that delivers the THV through the guiding tube and extension tubing. During a procedure, the physician will first crimp the THV onto the balloon of the Certitude Delivery System. The system is then inserted into the body, usually during a transapical (inserted through small incision under left breast) or transaortic (inserted through small incision in the top right side of the chest) approach. The THV is then deployed through the guiding tube to the site of the native stenotic aortic valve, where it is expanded and fixed in place.

Customers with questions regarding this recall may contact Edwards Customer Service at 1-800-424-3278, from 6:00 AM to 4:30 PM (Pacific Time).

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information: www.fda.gov


Related Content

News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
Subscribe Now